Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization.

Powell AB, Yadavilli S, Saunders D, Van Pelt S, Chorvinsky E, Burga RA, Albihani S, Hanley PJ, Xu Z, Pei Y, Yvon ES, Hwang EI, Bollard CM, Nazarian J, Cruz CRY.

J Transl Med. 2019 Sep 23;17(1):321. doi: 10.1186/s12967-019-2055-4.

2.

An exploratory cost-effectiveness analysis: Comparison between a midwife-led birth unit and a standard obstetric unit within the same hospital in Belgium.

Isaline G, Marie-Christine C, Rudy VT, Caroline D, Yvon E.

Midwifery. 2019 Aug;75:117-126. doi: 10.1016/j.midw.2019.05.004. Epub 2019 May 7.

PMID:
31100483
3.

Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.

Burga RA, Yvon E, Chorvinsky E, Fernandes R, Cruz CRY, Bollard CM.

Clin Cancer Res. 2019 Jul 15;25(14):4400-4412. doi: 10.1158/1078-0432.CCR-18-3183. Epub 2019 Apr 22.

PMID:
31010834
4.

Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution.

Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, Olson A, Nieto Y, Ciurea S, Popat U, Ahmed S, Champlin R, Ramos J, Nishimoto M, Ma H, Ke Z, Thall P, Khoury JD, Negrin R, Andersson B, Parmar S.

Oncotarget. 2018 Nov 2;9(86):35611-35622. doi: 10.18632/oncotarget.26242. eCollection 2018 Nov 2.

5.

Ex vivo generation of umbilical cord blood T regulatory cells expressing the homing markers CD62L and cutaneous lymphocyte antigen.

Kellner JN, Yvon E, Parmar S.

Oncotarget. 2018 Sep 14;9(72):33694-33701. doi: 10.18632/oncotarget.26097. eCollection 2018 Sep 14.

6.

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.

Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ.

Br J Haematol. 2017 May;177(3):457-466. doi: 10.1111/bjh.14570. Epub 2017 Mar 14.

7.

Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma.

Yvon ES, Burga R, Powell A, Cruz CR, Fernandes R, Barese C, Nguyen T, Abdel-Baki MS, Bollard CM.

Cytotherapy. 2017 Mar;19(3):408-418. doi: 10.1016/j.jcyt.2016.12.005. Epub 2017 Jan 19.

PMID:
28109751
8.

Long-term motor, functional, and academic outcome following childhood ischemic and hemorrhagic stroke: A large rehabilitation center-based retrospective study.

Yvon E, Lamotte D, Tiberghien A, Godard I, Mardaye A, Laurent-Vannier A, Agostini M, Chevignard M.

Dev Neurorehabil. 2018 Feb;21(2):83-90. doi: 10.1080/17518423.2016.1247923. Epub 2016 Nov 14.

PMID:
27841719
9.

A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy.

Alsuliman A, Appel SH, Beers DR, Basar R, Shaim H, Kaur I, Zulovich J, Yvon E, Muftuoglu M, Imahashi N, Kondo K, Liu E, Shpall EJ, Rezvani K.

Cytotherapy. 2016 Oct;18(10):1312-24. doi: 10.1016/j.jcyt.2016.06.012. Epub 2016 Aug 3.

PMID:
27497700
10.

Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.

Burga RA, Nguyen T, Zulovich J, Madonna S, Ylisastigui L, Fernandes R, Yvon E.

Cytotherapy. 2016 Nov;18(11):1410-1421. doi: 10.1016/j.jcyt.2016.05.018. Epub 2016 Jul 12. Review.

PMID:
27421740
11.

Gene Modification of Human Natural Killer Cells Using a Retroviral Vector.

Kellner JN, Cruz CR, Bollard CM, Yvon ES.

Methods Mol Biol. 2016;1441:203-13. doi: 10.1007/978-1-4939-3684-7_17.

PMID:
27177668
12.

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.

Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, Lewis ID, Brenner MK, Brown MP.

Mol Ther. 2016 Jun;24(6):1135-1149. doi: 10.1038/mt.2016.63. Epub 2016 Mar 29.

13.

All-in-one processing of heterogeneous human cell grafts for gene and cell therapy.

Lukianova-Hleb EY, Yvon ES, Shpall EJ, Lapotko DO.

Mol Ther Methods Clin Dev. 2016 Mar 16;3:16012. doi: 10.1038/mtm.2016.12. eCollection 2016.

14.

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.

Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ.

Blood. 2015 May 7;125(19):2885-92. doi: 10.1182/blood-2015-01-607366. Epub 2015 Mar 16.

15.

Cord blood: a promising source of allogeneic natural killer cells for immunotherapy.

Shaim H, Yvon E.

Cytotherapy. 2015 Jan;17(1):1-2. doi: 10.1016/j.jcyt.2014.12.001. No abstract available.

PMID:
25527863
16.

Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo.

Parmar S, Liu X, Najjar A, Shah N, Yang H, Yvon E, Rezvani K, McNiece I, Zweidler-McKay P, Miller L, Wolpe S, Blazar BR, Shpall EJ.

Blood. 2015 Feb 26;125(9):1502-6. doi: 10.1182/blood-2014-10-603449. Epub 2014 Nov 26.

17.

BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.

Gargett T, Fraser CK, Dotti G, Yvon ES, Brown MP.

J Immunother. 2015 Jan;38(1):12-23. doi: 10.1097/CJI.0000000000000061.

PMID:
25415284
18.

Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking.

Martin-Antonio B, Najjar A, Robinson SN, Chew C, Li S, Yvon E, Thomas MW, Mc Niece I, Orlowski R, Muñoz-Pinedo C, Bueno C, Menendez P, Fernández de Larrea C, Urbano-Ispizua A, Shpall EJ, Shah N.

Cell Death Differ. 2015 Jan;22(1):96-107. doi: 10.1038/cdd.2014.120. Epub 2014 Aug 29.

19.

Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD.

Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani K.

Blood. 2014 Sep 25;124(13):2034-45. doi: 10.1182/blood-2014-04-571125. Epub 2014 Jul 22.

20.

Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.

Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, Gao X, Guo L, Yvon E, Hicks J, Liu H, Dotti G, Metelitsa LS.

Blood. 2014 Oct 30;124(18):2824-33. doi: 10.1182/blood-2013-11-541235. Epub 2014 Jul 21.

21.

FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells.

Liu X, Robinson SN, Setoyama T, Tung SS, D'Abundo L, Shah MY, Yang H, Yvon E, Shah N, Yang H, Konopleva M, Garcia-Manero G, McNiece I, Rezvani K, Calin GA, Shpall EJ, Parmar S.

Bone Marrow Transplant. 2014 Jun;49(6):793-9. doi: 10.1038/bmt.2014.57. Epub 2014 Apr 7.

22.

Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.

Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, Melenhorst J, Barrett AJ, Ito S, Foster A, Savoldo B, Yvon E, Carrum G, Ramos CA, Krance RA, Leung K, Heslop HE, Brenner MK, Bollard CM.

Clin Cancer Res. 2014 Apr 15;20(8):2215-25. doi: 10.1158/1078-0432.CCR-13-3205. Epub 2014 Feb 26.

23.

Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.

Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ.

Cytotherapy. 2014 Jan;16(1):90-100. doi: 10.1016/j.jcyt.2013.07.009. Epub 2013 Oct 26.

24.

T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.

Geldres C, Savoldo B, Hoyos V, Caruana I, Zhang M, Yvon E, Del Vecchio M, Creighton CJ, Ittmann M, Ferrone S, Dotti G.

Clin Cancer Res. 2014 Feb 15;20(4):962-71. doi: 10.1158/1078-0432.CCR-13-2218. Epub 2013 Dec 13.

25.

Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.

Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ.

PLoS One. 2013 Oct 18;8(10):e76781. doi: 10.1371/journal.pone.0076781. eCollection 2013.

26.

Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.

Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant FA, Brawley VS, Byrd TT, Krebs S, Wu MF, Liu H, Heslop HE, Gottschalk S, Yvon E, Ahmed N.

Mol Ther. 2013 Nov;21(11):2087-101. doi: 10.1038/mt.2013.185. Epub 2013 Aug 13. Erratum in: Mol Ther. 2014 May;22(5):1063. Gottachalk, Stephen [corrected to Gottschalk, Stephen].

27.

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia.

Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, Lee D, Yvon E, Finney H, Lawson A, Brenner M, Biondi A, Biagi E, Rousseau R.

Adv Hematol. 2012;2012:683065. doi: 10.1155/2012/683065. Epub 2012 Jan 5.

28.

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK.

Blood. 2011 Dec 1;118(23):6050-6. doi: 10.1182/blood-2011-05-354449. Epub 2011 Oct 7.

29.

Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination.

Huye LE, Nakazawa Y, Patel MP, Yvon E, Sun J, Savoldo B, Wilson MH, Dotti G, Rooney CM.

Mol Ther. 2011 Dec;19(12):2239-48. doi: 10.1038/mt.2011.179. Epub 2011 Aug 30.

30.

Women's desire for children in an HIV population: a clinical pilot study in Burkina Faso.

Lemoine C, Willems N, Alain DH, Karama R, Somda I, Englert Y.

Curr HIV Res. 2011 Jul;9(5):346-51. Erratum in: Curr HIV Res. 2014;12(6):436. Caroline, Lemoine [corrected to Lemoine, Caroline]; Nathalic, Willems [corrected to Willems, Nathalie]; Diedon, Hien Alain [corrected to Alain, Diedon Hien]; Robert, Karama [corrected to Karama, Robert]; Idovide, Somda [corrected to Somda, Idovide]; Yvon,.

PMID:
21827386
31.

Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia.

Okur FV, Yvon E, Biagi E, Dotti G, Carrum G, Heslop H, Mims MP, Fratantoni JC, Peshwa MV, Li L, Brenner MK.

Cytotherapy. 2011 Oct;13(9):1128-39. doi: 10.3109/14653249.2011.592523. Epub 2011 Jul 12.

32.

An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies.

Ramos CA, Asgari Z, Liu E, Yvon E, Heslop HE, Rooney CM, Brenner MK, Dotti G.

Stem Cells. 2010 Jun;28(6):1107-15. doi: 10.1002/stem.433.

33.

Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.

Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Goodell MA, Heslop HE, Brenner MK.

Leukemia. 2010 Mar;24(3):563-72. doi: 10.1038/leu.2009.281. Epub 2010 Jan 14.

34.

Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression.

Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Andreeff M, Goodell MA, Heslop HE, Brenner MK.

Mol Cancer. 2009 Nov 18;8:106. doi: 10.1186/1476-4598-8-106.

35.

Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells.

Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Dutour A, Anichini A, Dotti G, Brenner MK.

Clin Cancer Res. 2009 Sep 15;15(18):5852-60. doi: 10.1158/1078-0432.CCR-08-3163. Epub 2009 Sep 8.

36.

Tumor necrosis factor-alpha induces RelA degradation via ubiquitination at lysine 195 to prevent excessive nuclear factor-kappaB activation.

Fan Y, Mao R, Zhao Y, Yu Y, Sun W, Song P, Shi Z, Zhang D, Yvon E, Zhang H, Fu S, Yang J.

J Biol Chem. 2009 Oct 23;284(43):29290-7. doi: 10.1074/jbc.M109.018994. Epub 2009 Aug 25.

37.

Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S.

Mol Ther. 2009 Oct;17(10):1779-87. doi: 10.1038/mt.2009.133. Epub 2009 Jun 16.

38.

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.

Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK.

Nat Med. 2008 Nov;14(11):1264-70. doi: 10.1038/nm.1882. Epub 2008 Nov 2.

39.

A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma.

Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, Yvon E, Brenner M, Rousseau R.

J Immunother. 2008 Nov-Dec;31(9):812-9. doi: 10.1097/CJI.0b013e3181869893.

PMID:
18833006
40.

Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy.

Fujita Y, Leen AM, Sun J, Nakazawa Y, Yvon E, Heslop HE, Brenner MK, Rooney CM.

J Immunother. 2008 Sep;31(7):665-74. doi: 10.1097/CJI.0b013e318181b4bd.

41.

Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin.

Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, Yvon E, Brenner M, Rousseau R.

J Immunother. 2007 Feb-Mar;30(2):227-33.

PMID:
17471169
42.

Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.

Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, Yvon E, Weiss H, Cobbold M, Gaspar HB, Rooney C, Kuehnle I, Ghetie V, Schindler J, Krance R, Heslop HE, Veys P, Vitetta E, Brenner MK.

Blood. 2006 Sep 15;108(6):1797-808. Epub 2006 Jun 1.

43.

[Immunotherapy of poor-prognosis neuroblastoma in children: from bench to bedside].

Rousseau R, Combaret V, Yvon E, Schell M, Philip I, Puisieux A, Frappaz D, Philip T, Bergeron C.

Bull Cancer. 2006 Feb;93(2):153-61. Review. French.

44.

Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.

Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK.

Blood. 2006 Feb 15;107(4):1332-41. Epub 2005 Oct 25.

45.

Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.

Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner M.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6916-23.

46.

Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells.

Li LH, Biagi E, Allen C, Shivakumar R, Weiss JM, Feller S, Yvon E, Fratantoni JC, Liu LN.

Cancer Gene Ther. 2006 Feb;13(2):215-24.

PMID:
16082377
47.

Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

Dotti G, Savoldo B, Pule M, Straathof KC, Biagi E, Yvon E, Vigouroux S, Brenner MK, Rooney CM.

Blood. 2005 Jun 15;105(12):4677-84. Epub 2005 Feb 15.

48.

Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.

Biagi E, Dotti G, Yvon E, Lee E, Pule M, Vigouroux S, Gottschalk S, Popat U, Rousseau R, Brenner M.

Blood. 2005 Mar 15;105(6):2436-42. Epub 2004 Nov 9.

PMID:
15536147
49.

Antigen-induced regulatory T cells.

Vigouroux S, Yvon E, Biagi E, Brenner MK.

Blood. 2004 Jul 1;104(1):26-33. Epub 2004 Mar 16. Review.

PMID:
15026316
50.

Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes.

Vigouroux S, Yvon E, Wagner HJ, Biagi E, Dotti G, Sili U, Lira C, Rooney CM, Brenner MK.

J Virol. 2003 Oct;77(20):10872-80.

Supplemental Content

Support Center